Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allen Lieberman

Allergy & Immunology Austin, TX Medical Doctor

NPI 1922075787 CMS profile 223646

10801 North MD PAC Expressway, Building II Suite 150, Austin, TX 78759

Open in the dashboard

General payments

$38,731

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$188,179 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Allen Lieberman of Austin, TX is reported in the CMS Open Payments database as having received $38,731 across 164 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $188,179 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,484 37
2024 General $267 12
2023 General $372 14
2022 General $432 17
2021 General $5,918 18
2020 General $4,721 12
2019 General $18,536 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen Lieberman
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Allen Lieberman were reported at $8,484. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Allen Lieberman Allergy & Immunology median Middle half National median
2019 $18,536 $594 $163–$1,512 $163
2020 $4,721 $426 $106–$1,233 $114
2021 $5,918 $638 $157–$1,708 $132
2022 $432 $790 $205–$1,961 $149
2023 $372 $852 $220–$2,147 $160
2024 $267 $865 $203–$2,267 $164
2025 $8,484 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $24,892 69 payments
  2. ARS Pharmaceuticals Operations, Inc. $5,539 11 payments
  3. Genzyme Corporation $4,555 14 payments
  4. kaleo, Inc. $2,656 19 payments
  5. Genentech USA, Inc. $277 7 payments
  6. AstraZeneca Pharmaceuticals LP $251 14 payments
  7. GlaxoSmithKline, LLC. $185 10 payments
  8. Novartis Pharmaceuticals Corporation $163 9 payments
  9. Phadia US Inc. $57 3 payments
  10. ALK-Abello, Inc $44 2 payments
  11. Other $111 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,341 14 payments
  2. Food and Beverage $4,213 130 payments
  3. Travel and Lodging $3,407 17 payments
  4. Consulting Fee $2,771 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $24,713 63 payments
  2. NEFFY $5,539 11 payments
  3. DUPIXENT Immunology $4,206 10 payments
  4. AUVI-Q Allergy $2,312 6 payments
  5. DUPIXENT Immunology $431 7 payments
  6. AUVI-Q Allergy $344 13 payments
  7. Xolair Immunology $277 7 payments
  8. DUPIXENT Immunology And Inflammation $179 6 payments
  9. TRELEGY ELLIPTA $155 9 payments
  10. XOLAIR Respiratory $111 7 payments
  11. Other $605 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record